Summary:

Summary Yesterday, AGEN presented updated data on its lead candidate, an anti-CTLA-4 at ASCO-GI23 The AGEN ASCO-GI23 presentation included expanded data from the Phase 1a/1b trial expansion cohort in MSS-CRC Key publicly available data from the presentation is provided below. Want more AGEN analysis and trade ideas? Sign up for one of our paid subscriptions HERE  and save with our current promotion Sign up for a BPIQ Pro account and get access to our BPIQ Pro post HERE , with

Article being drafted

This weekend we have the ASCO-GI biomedical meeting happening with some new data coming. See our full ASCO-GI post with catalyst readouts . See below for a table full of major events you should keep an eye on that are expected in the coming weeks.

Summary Recently we posted an article about upcoming gastro readouts including those at ASCO-GI and the upcoming MRK & SGEN PDUFA - HERE   One readout coming at ASCO-GI is from AGEN's lead asset botensilimab  (anti-CTLA-4) in combination with AGEN's anti-PD1 (balstilimab) Botensilimab is currently in a Phase 2 trial, and the ASCO-GI presentation will include expanded data from the Phase 1a/1b trial expansion cohort Here we look at how the Bot/Bal combo data has looked in the

Article currently in progress (1/17/23) Summary: ASCO-GI starts this Thursday, January 19, 2023 This conference focuses on indications including stomach cancer, gastrointestinal cancer, esophageal cancer, and colorectal cancer ( https://conferences.asco.org/gi/program ) In past years, big readouts have happened at this conference including from several Phase 3 trials On Thursday Jan 19 there is also a PDUFA for a GI indication: the SGEN and MRK PDUFA for Tukysa (Tucatinib) to

(Posted 10:20am CST) $XBI $80.99 | -0.17% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

(Posted 10:20am CST) $XBI $80.99 | -0.17% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

$XBI $80.99 | +5.81% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates # Pipeline Updates #LXRX +41.8%...

$XBI $80.99 | +5.81% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates # Pipeline Updates #LXRX +41.8%...

$XBI $74.80 | +1.0% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX +1.6% Novavax COVID-19 Data...

$XBI $74.80 | +1.0% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX +1.6% Novavax COVID-19 Data...

$XBI $67.03 | -4.60% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #GRTS -0.4% Gritstone Announces...

$XBI $67.03 | -4.60% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #GRTS -0.4% Gritstone Announces...

Summary Over 40 Smid-Cap companies currently have active trials involving COVID therapeutics (this includes small molecules and...

American Association for Cancer Research (AACR) presentations are happening this weekend and into early next week (see image below for a...